3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors

US9695171B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Paul Galatsis · Newton, US
• Matthew Merrill Hayward · Old Lyme, US
• Bethany Lyn Kormos · Somerville, US
• Travis T. Wager · Brookline, US
• Lei Zhang · Beijing, CN
• Jaclyn Louise Henderson · Cambridge, US
• Ravi G. Kurumbail · East Lyme, US
• Patrick Robert Verhoest · Newton, US
• Antonia Friederike Stepan · Providence, US

Key dates

• Filing date: Dec 3, 2014
• Grant date: Jul 4, 2017
• Expiry date: Dec 3, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D519/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereofwherein R1, R2, R3, R4 and X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.